Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - SteadyMed Ltd. | a16-20035_1ex99d1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 18, 2016
SteadyMed Ltd.
(Exact name of registrant as specified in its charter)
|
Israel |
|
001-36889 |
|
Not applicable |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer |
5 Oppenheimer Street
Rehovot 7670105, Israel
(Address of principal executive offices, including zip code)
925-272-4999
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
On October 18, 2016, SteadyMed Ltd. (the Company) will exhibit a poster providing an overview of its development of Trevyent®, its lead drug product candidate for the treatment of Pulmonary Arterial Hypertension (PAH), and of its PatchPump technology at the Parenteral Drug Association Conference in Huntington Beach, California. The poster includes data relating to the Company’s Registration Stability Lot program and ongoing Development Stability Program for Trevyent. A copy of the poster to be presented at the conference is attached to this Current Report on Form 8-K as Exhibit 99.1.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit |
|
Exhibit Description |
|
99.1 |
|
Conference Poster |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
STEADYMED LTD. |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ David W. Nassif |
|
Date: October 18, 2016 |
|
David W. Nassif |
|
|
|
Chief Financial Officer |